Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?

References

• JCVI statement on vaccination of children aged 5 to 11 years old. Department of Health and Social Care, Government of UK, published 16th Feb 2022. https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-aged-5-to-11/jcvi-statement-on-vaccination-of-children-aged-5-to-11-years-old. Accessed 22 March 2022.
   Google Scholar
• Merchant H. Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions. Postgrad Med J. 2021.
   PubMed Web of Science ®Google Scholar
• Merchant H (2021). Myocarditis followed by CoViD-19 vaccines: a cause for concern or a reversible minor effect? BMJ 2021;373:n1244/rr-10, https://www.bmj.com/content/373/bmj.n1244/rr-10
   Google Scholar
• Diaz et al., (2021). Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021;326(12):1210–1212. https://jamanetwork.com/journals/jama/fullarticle/2782900
   Google Scholar
• Merchant H (2021). Autoimmune damage to the nerves following Covid vaccines: EMA issued warning to patients and healthcare professionals. BMJ 2021;374:n1786/rr-0. https://www.bmj.com/content/374/bmj.n1786/rr-0
   Google Scholar
• Merchant H (2021). Might post-injection distribution of CoViD vaccines to the brain explain the rare fatal events of cerebral venous sinus thrombosis (CVST)? BMJ 2021;373:n958/rr-1 https://www.bmj.com/content/373/bmj.n958/rr-1
   Google Scholar
• Flu vaccine to be given to all UK children. Guardian, 25 July 2012. Available at: https://www.theguardian.com/society/2012/jul/25/flu-vaccine-all-uk-children. Accessed 22 March 2022.
   Google Scholar
• Hawkes N. UK stands by nasal flu vaccine for children as US doctors are told to stop using it. BMJ 2016;353:i3546. https://doi.org/10.1136/bmj.i3546.
   PubMedGoogle Scholar
• Lancaster University intranasal vaccine offers promise to block COVID-19 where it starts. Lancaster University, 10th August 2021. Last accessed on 22nd March 2022 at https://www.lancaster.ac.uk/news/lancaster-university-intranasal-vaccine-offers-promise-to-block-covid-19-where-it-starts
   Google Scholar
• Rubin, R (2021). COVID-19 Vaccine Nasal Spray. JAMA. 2021;326(12):1138. https://jamanetwork.com/journals/jama/fullarticle/2784523
   Google Scholar
• McGregor G (2021). Chinese pharma company is starting trials of an inhaled COVID-19 vaccine. Fortune, April 19, 2021. Last accessed on 22nd March 2022 at https://fortune.com/2021/04/19/covid-19-vaccine-china-cansino-inhale-nasal-spray/
   Google Scholar
• BBV154 - a novel adenovirus vectored, intranasal vaccine for COVID-19. Bharat Biotech, last accessed on 22nd March 2022 at https://www.bharatbiotech.com/intranasal-vaccine.html
   Google Scholar
• The Covid Vaccine We Need Now May Not Be a Shot. The New York Times, 2nd February 2021. Last accessed: 22nd March 2022 at https://www.nytimes.com/2022/02/02/health/covid-vaccine-nasal.html
   Google Scholar
• Smith N and Styllis G (2021). Taiwan joins race to develop nasal vaccine as trials suggest it could be more effective than a jab. Telegraph, 7th October 2021. Last accessed: 22nd March 2022 at https://www.telegraph.co.uk/global-health/science-and-disease/taiwan-joins-race-develop-nasal-vaccine-trials-suggest-could/.
   Google Scholar
• A 100% French nasal vaccine against COVID-19 yields positive pre­-clinical results. INRAE, France, 17 September 2021. Last accessed: 22nd March 2022 at https://www.inrae.fr/en/news/100-french-nasal-vaccine-against-covid-19-yields-positive-pre-clinical-results.
   Google Scholar
• Chappell et al., (2022). Immunocompromised children and young people are at no increased risk of severe COVID-19. Journal of Infection 84 (2022) 31–39. https://www.sciencedirect.com/science/article/pii/S016344532100548X.
   Google Scholar
• Merchant HA, Kow CS, Hasan SS. COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK. Expert Rev Respir Med. 2021;15(8):973–978. https://doi.org/10.1080/17476348.2021.1890035.
   PubMed Web of Science ®Google Scholar
• Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal). Summary of product characteristics, AstraZeneca. Last accessed: 22nd March 2022 at: https://www.medicines.org.uk/emc/medicine/29112.
   Google Scholar
• Hyde Z (2020).COVID-19, children and schools: overlooked and at risk. Med J Aust.213(10),444-446.e1. https://doi.org/10.5694/mja2.50823.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MU, Stiboy E, Hassan MZ, Chan M, Islam MS, Haider N, Jaffe A, Homaira N. Epidemiology of COVID-19 infection in young children under five years: a systematic review and meta-analysis. Vaccine. 2021;39(4):667–677. https://doi.org/10.1016/j.vaccine.2020.11.078.
   PubMed Web of Science ®Google Scholar
• Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ, Britton PN, Bartlett AW. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020;52(7):801–808. https://doi.org/10.1016/j.pathol.2020.08.001.
   PubMed Web of Science ®Google Scholar
• Keeling MJ, Tildesley MJ, Atkins BD, Penman B, Southall E, Guyver-Fletcher G, Holmes A, McKimm H, Gorsich EE, Hill EM, Dyson L (2021). The impact of school reopening on the spread of COVID-19 in England. Phil Trans R Soc B. 2021. https://doi.org/10.1098/rstb.2020.0261.
   Web of Science ®Google Scholar
• Investigation of SARS-CoV-2 variants of concern: technical briefings. Public Health England, 17th September 2021. Last accessed: 22nd March 2022 at: https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201.
   Google Scholar
• Munro APS, Janani L, Cornelius V Aley PK, COV-BOOST study group, et al., Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–2276https://doi.org/10.1016/S0140-6736(21)02717-3.
   PubMed Web of Science ®Google Scholar
• Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant. European Medicines Agency, 11th January 2022. Last accessed: 22nd March 2022 at: https://www.ema.europa.eu/en/news/preliminary-data-indicate-covid-19-vaccines-remain-effective-against-severe-disease-hospitalisation.
   Google Scholar
• Influenza vaccine effectiveness. The European Centre for Disease Prevention and Control, European Union. Last accessed: 22nd March 2022 at https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccine-effectiveness.
   Google Scholar
• Children’s vaccine 87% effective against circulating flu strain. Public Health England, 22nd February 2019. Last accessed: 22nd March 2022 at https://www.gov.uk/government/news/childrens-vaccine-87-effective-against-circulating-flu-strain.
   Google Scholar
• Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children. ClinicalTrials.gov Identifier: NCT00192205. https://clinicaltrials.gov/ct2/show/NCT00192205.
   Google Scholar
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age. ClinicalTrials.gov Identifier: NCT00128167. https://www.clinicaltrials.gov/ct2/show/NCT00128167.
   Google Scholar